Breast Cancer PSMA PET
ConditionTriple Negative Breast Cancer
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexFemale
Age18-90
SponsorAhmad Shariftabrizi
About this trial
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.
Eligibility criteria
Qualifiers
Female >= 18 years of age
Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.
Disqualifiers
Patients with known active other malignancy.
Unable to tolerate PET/CT procedure.
Pregnant or breastfeeding.
Patients with any medical condition that might compromise the safety of subject during PET acquisitions.
Trial design
Treatments tested in this trial
- PET imaging
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Ahmad Shariftabrizi
Lead sponsor
University of Iowa
Sponsor institution
Progenics Pharmaceuticals, Inc.
Collaborator
Source ClinicalTrials.gov